Cargando…

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-α) and the angiogenic factor vascular endothelial growth factor (VEGF). This study invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eisen, T, Boshoff, C, Mak, I, Sapunar, F, Vaughan, M M, Pyle, L, Johnston, S R D, Ahern, R, Smith, I E, Gore, M E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374399/ https://www.ncbi.nlm.nih.gov/pubmed/10732751 http://dx.doi.org/10.1054/bjoc.1999.1004

Ejemplares similares

The treatment of advanced renal cell cancer with high-dose oral thalidomide
por: Stebbing, J, et al.
Publicado: (2001)

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
por: Allen, M J, et al.
Publicado: (2000)

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
por: Gibbs, D D, et al.
Publicado: (2002)

Thalidomide Prevents the Progression of Peritoneal Fibrosis in Mice
por: Arai, Hideyuki, et al.
Publicado: (2011)

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
por: Verheul, H M W, et al.
Publicado: (1999)

Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia
por: Ansari, Saqib H., et al.
Publicado: (2022)

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
por: Waters, J S, et al.
Publicado: (2004)

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma
por: Morris, S L, et al.
Publicado: (2004)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Thalidomide—Then and Now: Case Report of a Woman With Thalidomide Embryopathy and Review of Current Thalidomide Uses
por: Malik, Sara, et al.
Publicado: (2021)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

Is the Low-Thalidomide Dose MPT Regimen Beneficial?
por: Min, Chang-Ki
Publicado: (2011)

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
por: Cameron, D A, et al.
Publicado: (2001)

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
por: Drake, M J, et al.
Publicado: (2003)

Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma
por: Zhang, Shiwu, et al.
Publicado: (2008)

Thalidomide and neurotrophism
por: Soper, Judith R., et al.
Publicado: (2018)

Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
por: Cao, Z, et al.
Publicado: (1999)

Telomerase activity in melanoma and non-melanoma skin cancer
por: Parris, C N, et al.
Publicado: (1999)

Rethinking thalidomide.
Publicado: (1995)

Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression
por: Hofmann, U B, et al.
Publicado: (1999)

Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature
por: Tempfer, Clemens B., et al.
Publicado: (2017)

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
por: Ahmed, F. Y., et al.
Publicado: (1996)

Dose-dependent thalidomide induced bradycardia in young erythema nodosum leprosum patient
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019)

The role of genetic factors in predisposition to squamous cell cancer of the head and neck
por: Jefferies, S, et al.
Publicado: (1999)

Non-melanoma skin cancers and glucocorticoid therapy
por: Karagas, M R, et al.
Publicado: (2001)

Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma
por: Sisley, K, et al.
Publicado: (2000)

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
por: Johnston, S. R., et al.
Publicado: (1998)

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

Therapy of Angiosarcoma with Thalidomide and Lenalidomide
por: Mattes, M. Jules, et al.
Publicado: (2021)

Physics, chemistry, and Hirshfeld surface analyses of gamma-irradiated thalidomide to evaluate behavior under sterilization doses
por: Mussel, Valner A.F.S.N., et al.
Publicado: (2018)

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
por: Ravaud, A, et al.
Publicado: (1999)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response
por: Vestermark, LW, et al.
Publicado: (2008)

Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases
por: Kraehn, G M, et al.
Publicado: (2001)

Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients
por: Peng, Xiang, et al.
Publicado: (2017)

Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer
por: McFadyen, M C E, et al.
Publicado: (2001)

Thalidomide in Dermatology: Revisited
por: Hassan, Iffat, et al.
Publicado: (2015)

Ovarian cancer
por: Kerbrat, P, et al.
Publicado: (2001)

Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo
por: Guba, M, et al.
Publicado: (2000)

Death and Rebirth of the Thalidomide Molecule: A Case of Thalidomide-Induced Sensory Neuropathy
por: Kesserwani, Hassan
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9tfutoojq83rnnbjrarlhkene0